Leo, Zymeworks partner on bispecific antibodies

Leo Pharma A/S (Ballerup, Denmark) and Zymeworks Inc. (NYSE:ZYME; TSX:ZYME) partnered to discover and develop bispecific antibodies targeting cytokine signaling pathways to treat dermatology, autoimmune and inflammatory diseases.

The partners will use Zymeworks' Azymetric platform, which generates bispecific antibodies, and its EFFECT platform, a library of Fc modifications that modulate antibody-mediated immune responses...